FDA Remains Neutral On COVID-19 Boosters Ahead Of VRBPAC Meeting

FDA is not convinced about the efficacy of an additional shot of Pfizer’s approved COVID-19 vaccine, Comirnaty, for the general population, despite calls from the White House and Pfizer to roll out boosters. The agency released briefing documents ahead of its Friday (Sept. 17) meeting during which FDA’s Vaccines and Related Biological Products Advisory Committee will discuss Pfizer’s supplemental biological license application for a booster dose of Comirnaty. Pfizer proposes giving the third shot six months after people have received...